A Phase 1 Study of FluBHPVE6E7 Immunotherapy in Patients With HPV16- Associated Oropharyngeal Squamous Cell Carcinoma
Latest Information Update: 27 Sep 2024
At a glance
- Drugs Flu BHPV E6E7 (Primary) ; Flu BHPV E6E7 (Primary)
- Indications Human papillomavirus infections; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Proof of concept
- Sponsors BlueSky Immunotherapies
- 27 Sep 2024 New trial record